Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The Global Immune Checkpoint Inhibitors Market size is expected to reach $75.9 billion by 2027, rising at a market growth of 16.1% CAGR during the forecast period.
A checkpoint inhibitor is a kind of immunotherapy medicine that works by blocking proteins found on tumor cells that interfere with immune system activity. CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 are all immune checkpoint proteins that are blocked by immune checkpoint inhibitors (programmed death-ligand 1). Immune checkpoint inhibitors work by assisting the immune system in recognizing and attacking cancer cells by targeting checkpoint proteins.
In addition, immune checkpoint inhibitors work by assisting the immune system in recognizing and attacking cancer cells by targeting checkpoint proteins. Due to an increase in demand for optimum therapies for cancer treatment, advantageous payment policies provided by manufacturers and insurance providers in some countries, and an increase in cancer occurrence around the world, the demand for immune checkpoint inhibitors is increasing.
COVID-19 Impact Analysis
COVID-19 Pandemic was first recorded in 2019 in China, after the first appearance, the novel coronavirus rapidly spread across the world and caused severe harm to people as well as businesses. Patients experience a variety of symptoms as a result of this infection, ranging from minor to severe. Dry cough, fever, and exhaustion are some of the most prevalent symptoms. Breathing difficulties or difficulty in breathing, chest pain or pressure, and impairment of speech or movement are all dangerous signs. Moreover, the virus has a significant fatality potential in the geriatric population.
Additionally, COVID-19 has had a negative overall impact on the immune checkpoint inhibitors market, owing to a decrease in the number of cancer patients visiting hospitals and clinics for immune checkpoint inhibitor therapy (ICI), which has resulted in a decrease in demand for immune checkpoint inhibitor products.
Market Growth Factors:
Increasing prevalence of cancer across the world
Lung cancer has a terrible prognosis and is the biggest cause of cancer-related death worldwide. Progression-free survival (PFS) and survival rate are both restricted despite vigorous treatment. Immune checkpoint inhibitors (ICIs) targeting PD1, PDL1, and CTLA-4 have recently been available for a variety of malignancies. ICIs have transformed the treatment of cancer, including lung cancer, and have made a huge breakthrough. However, there are numerous debates about whether patients are best treated with ICIs in terms of monotherapy, combination therapy, and predictive biomarkers.
Immune checkpoint inhibitors have been found to be effective in the treatment of a variety of cancers, including breast, bladder, stomach, colon, liver, cervical, stomach, lung, skin, stomach, and rectal cancer.
Increasing geriatric population across the world
The increasing prevalence of the geriatric population across the world is one of the major concerns of healthcare infrastructures globally. As the age of a person increases, it makes their immune systems more fragile to various kinds of cancers, especially prostate cancer and lung cancer. The geriatric population is majorly more vulnerable to chronic diseases. As per the data shared by the United Nations Organization, in 2019, 703 million people of age 65 or more than that were recorded across the world. Moreover, this number is estimated to reach 1.5 billion by 2050 by the UNO.
Marketing Restraining Factor:
Lack of awareness among people
Cancer is a disease that are of various types, which can begin in practically any organ or tissue of the body and spread to other organs when abnormal cells proliferate uncontrollably, and invade surrounding areas of the body, and/or move to other organs. It is a very fatal disorder that can end up in life losses. One of the major concerns among healthcare practitioners across the world is that a significant population is not fully aware of the prevalence of various types of cancer, which further delays the diagnosis and hence, increases the death rate.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.3 Market Scope
1.4.1 Global Immune Checkpoint Inhibitors Market, by Application
1.4.2 Global Immune Checkpoint Inhibitors Market, by Type
1.4.3 Global Immune Checkpoint Inhibitors Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
18.104.22.168 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May - 2021, Dec) Leading Players
Chapter 4. Global Immune Checkpoint Inhibitors Market by Application
4.1 Global Lung Cancer Market by Region
4.2 Global Bladder Cancer Market by Region
4.3 Global Melanoma Market by Region
4.4 Global Hodgkin lymphoma Market by Region
4.5 Global Other Application Market by Region
Chapter 5. Global Immune Checkpoint Inhibitors Market by Type
5.1 Global PD-1 Inhibitor Market by Region
5.2 Global PD-L1 Inhibitor Market by Region
5.3 Global CTLA-4 Inhibitor Market by Region
Chapter 6. Global Immune Checkpoint Inhibitors Market by Region
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
126.96.36.199 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
188.8.131.52 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
184.108.40.206 Partnerships, Collaborations, and Agreements:
220.127.116.11 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
18.104.22.168 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
126.96.36.199 Approvals and Trials:
188.8.131.52 Acquisition and Mergers
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
184.108.40.206 Partnerships, Collaborations, and Agreements:
220.127.116.11 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.6 Partnerships, Collaborations and Agreements:
18.104.22.168 Approvals and Trials:
For more information about this report visit https://www.researchandmarkets.com/r/qh2zje
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900